Weight Loss Greater With Intermittent Fasting Than Calorie Restriction
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, March 31, 2025 -- An intermittent fasting (IMF) intervention yields modestly greater weight loss than daily caloric restriction (DCR) among adults with overweight or obesity, according to a study published online April 1 in the Annals of Internal Medicine.
Victoria A. Catenacci, M.D., from the University of Colorado Anschutz Medical Campus in Aurora, and colleagues compared the effects of 4:3 IMF versus DCR on changes in weight at 12 months with comprehensive behavioral support in a randomized clinical trial involving adults aged 18 to 60 years with a body mass index of 27 to 46 kg/m2. The IMF group was instructed to restrict energy intake by 80 percent on three nonconsecutive days per week, with no restriction on the other four days (4:3 IMF). The DCR group was instructed to match the weekly energy deficit by reducing daily energy intake by 34 percent. Both groups also received a high-intensity comprehensive behavioral weight loss program.
The study included 165 participants: 84 4:3 IMF and 81 DCR; 125 individuals completed the trial. The researchers found that at 12 months, 4:3 IMF showed greater reductions in weight than DCR in an intention-to-treat analysis (mean difference, 2.89 kg).
"4:3 IMF should be considered within the range of evidence-based dietary weight loss approaches," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-04-01 12:00
Read more

- Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
- ACC: Colorectal Cancer Tied to Higher Risk for Cardiovascular Death
- Lumpectomy Preserves Sexual Well-Being Among Breast Cancer Patients
- Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA
- Sarepta’s Gene Therapy, Elevidys, Under Scrutiny After Patient Death
- Major Job Cuts at NIOSH Pose Risks to Worker Safety, Critics Warn
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions